Deciphera Pharmaceuticals (NASDAQ:DCPH) Earns “Hold” Rating from Jonestrading

Deciphera Pharmaceuticals (NASDAQ:DCPH)‘s stock had its “hold” rating reissued by analysts at Jonestrading in a note issued to investors on Monday, Benzinga reports. They currently have a $25.60 target price on the stock. Jonestrading’s price target suggests a potential upside of 1.55% from the stock’s previous close.

DCPH has been the topic of a number of other reports. Stifel Nicolaus upped their price target on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. JPMorgan Chase & Co. lifted their price objective on shares of Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Wednesday, March 20th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $23.87.

Deciphera Pharmaceuticals Stock Up 72.1 %

DCPH traded up $10.56 during midday trading on Monday, hitting $25.21. 35,773,927 shares of the company were exchanged, compared to its average volume of 938,644. The firm has a market capitalization of $2.07 billion, a P/E ratio of -11.01 and a beta of 0.39. Deciphera Pharmaceuticals has a 1-year low of $9.90 and a 1-year high of $25.40. The firm’s 50 day moving average price is $15.59 and its 200-day moving average price is $14.35.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings data on Tuesday, February 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.04. The company had revenue of $48.30 million for the quarter, compared to the consensus estimate of $45.93 million. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The firm’s revenue was up 32.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.60) EPS. On average, sell-side analysts predict that Deciphera Pharmaceuticals will post -2.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Deciphera Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. raised its stake in Deciphera Pharmaceuticals by 96.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company’s stock valued at $26,000 after acquiring an additional 997 shares during the period. Quest Partners LLC bought a new stake in shares of Deciphera Pharmaceuticals during the fourth quarter valued at about $30,000. AJOVista LLC bought a new stake in shares of Deciphera Pharmaceuticals during the fourth quarter valued at about $76,000. Exchange Traded Concepts LLC increased its position in shares of Deciphera Pharmaceuticals by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 10,447 shares of the company’s stock valued at $169,000 after buying an additional 2,649 shares during the period. Finally, Aigen Investment Management LP bought a new stake in shares of Deciphera Pharmaceuticals during the third quarter valued at about $181,000. 70.96% of the stock is owned by hedge funds and other institutional investors.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.